Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis

ClinicalTrials.gov ID: NCT03122353

Public ClinicalTrials.gov record NCT03122353. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 24, 2026, 8:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind Study Comparing TOLMAR Calcipotriene and Betamethasone Suspension to Reference Listed Drug in the Treatment of Scalp Psoriasis

Study identification

NCT ID
NCT03122353
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Tolmar Inc.
Industry
Enrollment
699 participants

Conditions and interventions

Interventions

  • Calcipotriene and betamethasone suspension Drug
  • Taclonex Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 10, 2017
Primary completion
Nov 14, 2017
Completion
Nov 14, 2017
Last update posted
Mar 6, 2018

2017

United States locations

U.S. sites
34
U.S. states
16
U.S. cities
31
Facility City State ZIP Site status
Site 17 Hot Springs Arkansas 71913
Site 29 Fremont California 94538
Site 12 Los Angeles California 90036
Site 18 Sherman Oaks California 91403
Site 34 Denver Colorado 80220
Site 20 Boca Raton Florida 33486
Site 01 Brandon Florida 33511
Site 25 Coral Gables Florida 33134
Site 11 Hialeah Florida 33012
Site 26 Miami Florida 33126
Site 04 Miami Florida 33175
Site 05 Miramar Florida 33027
Site 02 Tampa Florida 33609
Site 03 Tampa Florida 33618
Site 23 Winter Park Florida 32792
Site 16 Plainfield Indiana 46168
Site 19 Olathe Kansas 66061
Site 33 Lake Charles Louisiana 70601
Site 27 Saint Joseph Missouri 64506
Site 14 Las Vegas Nevada 89106
Site 09 High Point North Carolina 27262
Site 28 Hazleton Pennsylvania 18201
Site 24 Upper Saint Clair Pennsylvania 15241
Site 32 Johnston Rhode Island 02919
Site 07 Anderson South Carolina 29621
Site 35 Mt. Pleasant South Carolina 29464
Site 21 Austin Texas 78759
Site 06 Dallas Texas 75234
Site 30 El Paso Texas 79902
Site 08 Murphy Texas 75094
Site 15 San Antonio Texas 78229
Site 31 San Antonio Texas 78229
Site 10 Salt Lake City Utah 84117
Site 22 Norfolk Virginia 23507

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03122353, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 6, 2018 · Synced Jul 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03122353 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →